Healthcare | Tuesday 31 March, 2015 6:48 am |

in Saudi Arabia, the Gulf Countries, North Africa and the Middle East

- Tabuk Pharmaceutical Manufacturing Company (“Tabuk”), one of the leading pharmaceutical companies in the Middle East and North Africa region (MENA) region, has entered into an exclusive license and distribution agreement with Innovus Pharmaceuticals, Inc., (“Innovus Pharma”).
This project is aligned with one of Tabuk Pharmaceuticals’ main strategic objectives: to expand its offering of innovative medicines in Saudi Arabia & MENA, by strengthening its position in its domestic market through partnerships with multinational companies. In so doing, Tabuk Pharmaceuticals continues to deliver on its mission to help improve the lives of patients.
This partnership illustrates our commitment to leverage our MENA-wide footprint and to serve multinational partners looking to maximize their potential in the region”. “It further enhances Tabuk Pharmaceuticals’ ability to maintain its momentum in MENA, in line with its growth strategy” said Mr. Ismail Bel-Bachir, CEO of Tabuk Pharmaceuticals.
Dr. Rana Azzam, Senior VP of Business Development added, “We are pleased to add Innovus’ unique products to our growing portfolio, and help address a large unmet medical need in the region. We look forward to start building market share and revenues from these products.”
Bassam Damaj, President and Chief Executive Officer of Innovus Pharma commented, "We are very excited about this major commercial partnership collaboration with Tabuk for our products. This type of product is in very high demand in the region and would is expected to be first in class in the region. Saudi Arabia is the largest market in the region and we expect significant potential revenue from this region. This partnership the sixth of many partnerships the Company is expected to announce in the near future and is yet another milestone in the Company’s execution of its international growth and making our products commercially available in a minimum of 40 countries by the end of 2015. "
According to the agreement, Innovus Pharma granted to Tabuk an exclusive license to market and sell Innovus Parma's topical treatment for premature ejaculation EjectDelay®, its product Sensum+® to increase penile sensitivity and Vesele® to increase sexual and cognitive health in Saudi Arabia, the Gulf Countries, North Africa, and the Middle East.
EjectDelay® for premature ejaculation is currently commercialized in the US and expected to be launched in Canada during the first half of 2015. Sensum+® for increasing penile sensitivity is currently commercial in the US, the UK, and Morocco. Vesele® for increasing sexual and cognitive health is currently commercialized in the US and the UK.

About Tabuk
Tabuk Pharmaceuticals Manufacturing Company develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products. Established in 1994 in Saudi Arabia, Tabuk Pharmaceuticals’ fast growth has allowed it to become a global company, with a strong focus on the Middle East and North Africa region. Today, it is one of the leading companies in Saudi Arabia ranking third among all pharmaceutical companies, is present in over 25 markets and employs over 2500 employees.
Tabuk has a strong R&D pipeline and a complete pharmaceutical portfolio in the MENA region, covering a wide range of therapeutic areas. The company has strengthened its presence by collaborating with multinational companies through vital drugsin-licensing.
For more information, visit Taboo's website at www.tabukpharmaceuticals.com

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, and two products in the pipeline including, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and FlutiCare™ OTC for Allergic Rhinitis.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com